Additive Antiangiogenesis Effect of Ginsenoside Rg3 with Low-dose Metronomic Temozolomide on Rat Glioma Cells Both in Vivo and in Vitro

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2016 Feb 14

PMID 26872471

Citations 25

Authors

Caixing Sun

Yang Yu

Lizhen Wang

Bin Wu

Liang Xia

Fang Feng

Zhiqiang Ling

Shihua Wang

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma is the most common and deadly primary brain tumor in adults. Low-dose,metronomic (LDM) temozolomide (TMZ) displays improved efficacy in the treatment of glioblastoma by targeting angiogenesis, but has a limited effect on recurrence. The antiangiogenesis drug ginsenoside Rg3 (RG3) is the main active ingredient of ginseng, a popular herbal medicine.

Methods: Using an in vitro and a rat model of an orthotopic glioma allograft, this study was to determine whether RG3 enhanced the antiangiogenesis activity of LDM TMZ in the treatment of glioblastoma.

Results: Our results showed that combined use of TMZ with RG3 displayed additive inhibition on proliferation of both human umbilical vein endothelial cells (HUVEC) and rat C6 glioma cells in vitro. They additively arrested cell cycle, increased apoptosis, and decreased VEGF-A and BCL-2 expression in HUVEC. Antiangiogenesis effect was also evaluated in the rat model of orthotopic glioma allograft, based upon markers including relative cerebral blood volume (rCBV) by magnetic resonance imaging (MRI), VEGF levels and microvessel density (MVD)/CD34 staining. LDM TMZ alone was potent in suppressing angiogenesis and tumor growth, whereas RG3 alone only had modest antiangiogenesis effects. Combined treatment significantly and additively suppressed angiogenesis, without additive inhibitory effects on allografted tumor growth.

Conclusions: These data provide evidence showing the efficacy of LDM TMZ on glioma treatment. The combined additive antiangiogenesis effect suggests that RG3 has the potential to further increase the efficacy of LDM TMZ in the treatment of glioblastoma.

Citing Articles

Ginsenoside Rg3 enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/AKT signaling pathway.

Li J, Yang B In Vitro Cell Dev Biol Anim. 2023; 59(1):19-30.

PMID: 36790693 DOI: 10.1007/s11626-023-00749-3.

Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells.

Shan K, Deng Y, Du Z, Yue P, Yang S Comput Math Methods Med. 2022; 2022:2813142.

PMID: 35799655 PMC: 9256322. DOI: 10.1155/2022/2813142.

Label-free study on the effect of a bioactive constituent on glioma cells in vitro using terahertz ATR spectroscopy.

Liao Y, Zhang M, Tang M, Chen L, Li X, Liu Z Biomed Opt Express. 2022; 13(4):2380-2392.

PMID: 35519255 PMC: 9045931. DOI: 10.1364/BOE.452952.

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors.

Busker S, Jager W, Poschner S, Mayr L, Al Jalali V, Gojo J Cancer Chemother Pharmacol. 2022; 89(5):617-627.

PMID: 35355137 PMC: 9054874. DOI: 10.1007/s00280-022-04424-4.

Novel molecules as the emerging trends in cancer treatment: an update.

Sekar P, Ravitchandirane R, Khanam S, Muniraj N, Cassinadane A Med Oncol. 2022; 39(2):20.

PMID: 34982273 DOI: 10.1007/s12032-021-01615-6.

References

Choi Y, Lee H, Kang D, Han I, Choi B, Cho W . Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep. 2013; 30(3):1362-70. DOI: 10.3892/or.2013.2555. View

Tolcher A, Gerson S, Denis L, Geyer C, Hammond L, Patnaik A . Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88(7):1004-11. PMC: 2376384. DOI: 10.1038/sj.bjc.6600827. View

Kim J, Kim J, Ko K, Kong D, Kang C, Kim M . Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006; 16(1):33-9. View

Yue P, Wong D, Wu P, Leung P, Mak N, Yeung H . The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol. 2006; 72(4):437-45. DOI: 10.1016/j.bcp.2006.04.034. View

Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-7. PMC: 300842. DOI: 10.1172/JCI9872. View

Thomsen H, Steffensen E, Larsson E . Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Acta Radiol. 2011; 53(1):95-101. DOI: 10.1258/ar.2011.110242. View

Kong D, Lee J, Kim J, Kim S, Kim W, Suh Y . Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010; 12(3):289-96. PMC: 2940595. DOI: 10.1093/neuonc/nop030. View

Di Nallo A, Vidiri A, Marzi S, Mirri A, Fabi A, Carapella C . Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases. J Exp Clin Cancer Res. 2009; 28:38. PMC: 2661315. DOI: 10.1186/1756-9966-28-38. View

Vera K, Djafari L, Faivre S, Guillamo J, Djazouli K, Osorio M . Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol. 2003; 15(1):161-71. DOI: 10.1093/annonc/mdh003. View

10.

Kim S, Seong S, Kim S . Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells. Oncol Lett. 2014; 7(4):1265-1269. PMC: 3961386. DOI: 10.3892/ol.2014.1826. View

11.

Sin S, Kim S, Kim S . Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells. Int J Oncol. 2012; 41(5):1669-74. DOI: 10.3892/ijo.2012.1604. View

12.

Nagasubramanian R, Dolan M . Temozolomide: realizing the promise and potential. Curr Opin Oncol. 2003; 15(6):412-8. DOI: 10.1097/00001622-200311000-00002. View

13.

Kim D, Jung K, Lee D, Yoon J, Choi K, Kwon S . 20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget. 2014; 5(12):4438-51. PMC: 4147336. DOI: 10.18632/oncotarget.2034. View

14.

Kim Y, Zhang D, Yang D . Biosynthesis and biotechnological production of ginsenosides. Biotechnol Adv. 2015; 33(6 Pt 1):717-35. DOI: 10.1016/j.biotechadv.2015.03.001. View

15.

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D . Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000; 105(8):R15-24. PMC: 517491. DOI: 10.1172/JCI8829. View

16.

Kurzen H, Schmitt S, Naher H, Mohler T . Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 2003; 14(7):515-22. DOI: 10.1097/00001813-200308000-00003. View

17.

Barajas Jr R, Cha S . Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. CNS Oncol. 2014; 3(6):407-19. PMC: 4277861. DOI: 10.2217/cns.14.44. View

18.

Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P . Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol. 2004; 131(1):31-40. DOI: 10.1007/s00432-004-0620-5. View

19.

Wang L, Li X, Song Y, Wang B, Zhang F, Yang R . Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to γ-radiation by targeting the nuclear factor-κB pathway. Mol Med Rep. 2015; 12(1):609-14. DOI: 10.3892/mmr.2015.3397. View

20.

Gahramanov S, Muldoon L, Li X, Neuwelt E . Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology. 2011; 261(3):796-804. PMC: 3219915. DOI: 10.1148/radiol.11103503. View